Lack of effect of vitamin E on serum creatine phosphokinase in patients with long-term tardive dyskinesia

International Clinical Psychopharmacology

Volumn 12, Issue 3, 1997, Pages 171-173

  Dorevitch, A ^a   Lerner, V ^b   Shalfman, M ^b   Kalian, M ^b  

^a Talbieh Mental Health Center   (Israel)

^b Jerusalem Mental Health Center Ezrath Nashim   (Israel)

Author keywords

Creatine phosphokinase; Tardive dyskinesia; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; BIPERIDEN; CHLORPROMAZINE; CREATINE KINASE; NEUROLEPTIC AGENT; PLACEBO; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CHRONIC PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPOTHESIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0030744280     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199705000-00008     Document Type: Article

References (14)

1. Bendich A and Machlin J (1988) Safety of oral intake of vitamin E. American Journal of Clinical Nutrition, 48, 612-619.
2. Bitton V and Melamed E (1984) Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. Journal of Clinical Psychiatry, 45, 356-357.
3. Briggs M (1974) Vitamin E supplements and fatigue. New England Journal of Medicine, 290, 579-580.
4. Cavanaugh JJ and Finlayson RE (1984) Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. American Journal of Psychiatry, 151, 925-926.
5. Dabiri LM, Pasta D, Darby JK and Mosbacher D (1994) Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. American Journal of Psychiatry, 151, 925-926.
6. Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, Blum A, Saenz RE and Wyatt RJ (1992) Treatment of tardive dyskinesia with vitamin E. American Journal of Psychiatry, 149, 773-777.
7. Egan MF, Dargham AA, Kirch DG and Wyatt RJ (1993) Serum creatine phosphokinase elevations in patients with tardive dyskinesia. British Journal of Psychiatry, 162, 551-553.
8. Elkashef AM, Ruskin PE, Bacher N and Barrett D (1990) Vitamin E in the treatment of tardive dyskinesia. American Journal of Psychiatry, 147, 505-506.
9. Lam LCW, Chiu HFK, Hung SF (1994) Vitamin E in the treatment of tardive dyskinesia: a replication study. The Journal of Nervous and Mental Disease, 182, 113-114.
10. Lohr JB, Cadet JL, Lohr MA, Larson L, Wasli E, Wade L, Hylton R, Vidoni C, Jeste DV and Wyatt RJ (1988) Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophrenia Bulletin, 14, 291-296.
11. Malas KL and Van Kammen DP (1982) Markedly elevated creatine phosphokinase levels after neuroleptic withdrawal. American Journal of Psychiatry, 139, 231-232.
12. Pearlman C, Wheadon D and Epstein S (1988) Creatine kinase elevation after neuroleptic treatment. American Journal of Psychiatry, 145, 1018-1019.
13. Salkeld RM (1979) Safety and tolerance of high-dose vitamin E administration in man: a review of the literature. Federal Registrar, 44, 16172.
14. Weiss B, Prozialeck LC and Wallace TL (1982) Interaction of drugs with calmodulin. Biochemical Pharmacology, 31, 2217-2226.